This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Avanir's CEO Presents At Citi 2012 Global Health Care Conference - Transcript

Taking a quick snapshot of our pipeline, you can see NUEDEXTA on the top there with FDA approval for the treatment of pseudobulbar affect. In addition, you can see NUEDEXTA or AVP-923 in Phase II studies for central neuropathic pain in multiple sclerosis. In regards to behavioral disturbances in Alzheimer’s, we’re currently working on our investigation on New Drug Application. We’re planning on filing that with the FDA in the second quarter of this year with the intent of enrolling our first patient in mid-to-late summer of this year. And, finally, our diabetic peripheral neuropathic pain, you may be aware that we announced a publication of our Phase III studies in diabetic peripheral neuropathic pain a number of weeks ago, that program looks very promising. However, we it on hold right now until we get the results of our neuropathic pain and multiple sclerosis. Additionally on the slide, you now see the addition of our deuterated dextromethorphan program. That is a preclinical asset that’s what we’ve planned on to moving that into the clinic as quickly as possible. And then, finally, our non-CNS related products ABREVA and Thravixa.

So a quick overview of the deal that we signed with Concert Pharmaceuticals this morning, it is an exclusive worldwide license agreement to develop and commercialize deuterated dextromethorphan. Concert is a privately-held company in Lexington, Massachusetts. We’re getting a several deuterated dextromethorphan compounds. And what’s very exciting for us is that deuterated dextromethorphan is a new chemical entity and therefore has the associated intellectual property with the new chemical entity and the existing patents lasts through 2030, with opportunities for extension, as well as additional patent applications in the future. And I’ll go into a little more detail on the deuterated technology later in the presentation.

So turning now to recent achievements of the company, as I mentioned at the onset, the launch of NUEDEXTA continues to go quite well. We have achieved a record prescriptions in December of over 5,600 prescriptions and over 6,000 in January, showing nice continued growth. If you take data point from early February, we’ve had over 1,600 prescriptions in that week alone. If you annualize the value of those prescriptions, it annualizes to a run rate of $37 million in NUEDEXTA sales, and that we continue to see – expect to continue to see growth in weekly and monthly prescriptions.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,078.37 +54.31 0.30%
S&P 500 2,114.91 +6.62 0.31%
NASDAQ 5,021.9030 +16.5120 0.33%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs